# US 2013/0156798 A1 · Peptide composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156798 A1
- Document ID: US20130156798A1
- Status: Published application
- Kind: A1
- Application number: 13/706,540
- Filed: 2012-12-06
- Published: 2013-06-20
- Earliest claimed: 2000-08-21
- Assignees: Apitope Technology (Bristol) Limited
- Inventors: David Wraith; Heather Barbara Streeter
- Web page: https://patentgrep.com/patent/US20130156798A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- G01N 33/505: {involving T-cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of inducing T cell tolerance to myelin basic protein in a subject in need of same which comprises the step of administering a peptide MBP 30-44 (SEQ ID NO: 1), MBP 83-99 (SEQ ID NO: 2) or MBP 131-145 (SEQ ID NO: 3) to the subject.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

A method according to claim 16 wherein the peptide is administered in multiple doses.

### Claim 19 (depends on 16, 18, 20)

A method according to claim 16, 18 or 20, wherein the peptide is administered intranasally.

### Claim 20 (depends on 16)

A method according to claim 16 wherein the peptide is administered following a dose-escalation protocol.

### Claim 21 (depends on 16)

The method according to claim 16 wherein the subject is HLA-DQ6 or HLA-DR2 positive.

### Claim 22 (depends on 16)

The method of claim 16 wherein the subject has Relapsing-Remitting multiple sclerosis.

### Claim 23 (depends on 16)

The method of claim 16 wherein the subject has Secondary Progressive multiple sclerosis.

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23 wherein the induction of T cell tolerance ameliorates one or more symptoms of the multiple sclerosis.

### Claim 25 (depends on 22, 23, 24)

The method of claim 22, 23 or 24 wherein the induction of T cell tolerance inhibits progression of the multiple sclerosis.